Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users

Yen Chi L Le, Mahbubur Rahman, Abbey Berenson

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

OBJECTIVE: To examine if early weight gain in depot medroxyprogesterone acetate (DMPA) users predicts continued excessive weight gain and to identify risk factors of early weight gain in DMPA users. METHODS: Depot medroxyprogesterone acetate users (N=240) were assessed before initiating contraception and every 3 months for 36 months. Early weight gain was defined as more than 5% baseline weight gain within 6 months of DMPA use. Mean weight gain at 6-month intervals was estimated based on early weight gain status (at or below 5% gain compared with above 5% gain). Multiple logistic and mixed-model regression analyses were used. RESULTS: About one-fourth of DMPA users had early weight gain. The mean weight gain of the at or below 5% group and above 5% group was 0.63 kg and 8.04 kg, 1.48 kg and 10.86 kg, and 2.49 kg and 11.08 kg after 12, 24, and 36 months (P<.001 at all observations), respectively. Early weight gainers also had a much steeper slope of weight gain over time than the regular weight gainers (0.35 kg/month compared with 0.08 kg/month, P<.001). Risk factors for early weight gain were body mass index less than 30 (odds ratio [OR] 4.00, 95% confidence interval [CI] 1.513-10.455), parity (OR 2.23, 95% CI:1.040-4.761), and self-reported increased appetite after 6 months of DMPA use (OR 3.06, 95% CI 1.505-6.214). CONCLUSION: Most DMPA users who gain excessive weight experience more than a 5% weight increase within 6 months. These data help physicians predict who is at risk of excessive gain and counsel them appropriately. LEVEL OF EVIDENCE: II.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalObstetrics and Gynecology
Volume114
Issue number2 PART 1
DOIs
StatePublished - Aug 2009

Fingerprint

Medroxyprogesterone Acetate
Weight Gain
Odds Ratio
Confidence Intervals
Weights and Measures
Appetite
Parity
Contraception
Body Mass Index
Logistic Models

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. / Le, Yen Chi L; Rahman, Mahbubur; Berenson, Abbey.

In: Obstetrics and Gynecology, Vol. 114, No. 2 PART 1, 08.2009, p. 279-284.

Research output: Contribution to journalArticle

@article{95a1ecfb946848a5a7ce214ede8339b6,
title = "Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users",
abstract = "OBJECTIVE: To examine if early weight gain in depot medroxyprogesterone acetate (DMPA) users predicts continued excessive weight gain and to identify risk factors of early weight gain in DMPA users. METHODS: Depot medroxyprogesterone acetate users (N=240) were assessed before initiating contraception and every 3 months for 36 months. Early weight gain was defined as more than 5{\%} baseline weight gain within 6 months of DMPA use. Mean weight gain at 6-month intervals was estimated based on early weight gain status (at or below 5{\%} gain compared with above 5{\%} gain). Multiple logistic and mixed-model regression analyses were used. RESULTS: About one-fourth of DMPA users had early weight gain. The mean weight gain of the at or below 5{\%} group and above 5{\%} group was 0.63 kg and 8.04 kg, 1.48 kg and 10.86 kg, and 2.49 kg and 11.08 kg after 12, 24, and 36 months (P<.001 at all observations), respectively. Early weight gainers also had a much steeper slope of weight gain over time than the regular weight gainers (0.35 kg/month compared with 0.08 kg/month, P<.001). Risk factors for early weight gain were body mass index less than 30 (odds ratio [OR] 4.00, 95{\%} confidence interval [CI] 1.513-10.455), parity (OR 2.23, 95{\%} CI:1.040-4.761), and self-reported increased appetite after 6 months of DMPA use (OR 3.06, 95{\%} CI 1.505-6.214). CONCLUSION: Most DMPA users who gain excessive weight experience more than a 5{\%} weight increase within 6 months. These data help physicians predict who is at risk of excessive gain and counsel them appropriately. LEVEL OF EVIDENCE: II.",
author = "Le, {Yen Chi L} and Mahbubur Rahman and Abbey Berenson",
year = "2009",
month = "8",
doi = "10.1097/AOG.0b013e3181af68b2",
language = "English (US)",
volume = "114",
pages = "279--284",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART 1",

}

TY - JOUR

T1 - Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users

AU - Le, Yen Chi L

AU - Rahman, Mahbubur

AU - Berenson, Abbey

PY - 2009/8

Y1 - 2009/8

N2 - OBJECTIVE: To examine if early weight gain in depot medroxyprogesterone acetate (DMPA) users predicts continued excessive weight gain and to identify risk factors of early weight gain in DMPA users. METHODS: Depot medroxyprogesterone acetate users (N=240) were assessed before initiating contraception and every 3 months for 36 months. Early weight gain was defined as more than 5% baseline weight gain within 6 months of DMPA use. Mean weight gain at 6-month intervals was estimated based on early weight gain status (at or below 5% gain compared with above 5% gain). Multiple logistic and mixed-model regression analyses were used. RESULTS: About one-fourth of DMPA users had early weight gain. The mean weight gain of the at or below 5% group and above 5% group was 0.63 kg and 8.04 kg, 1.48 kg and 10.86 kg, and 2.49 kg and 11.08 kg after 12, 24, and 36 months (P<.001 at all observations), respectively. Early weight gainers also had a much steeper slope of weight gain over time than the regular weight gainers (0.35 kg/month compared with 0.08 kg/month, P<.001). Risk factors for early weight gain were body mass index less than 30 (odds ratio [OR] 4.00, 95% confidence interval [CI] 1.513-10.455), parity (OR 2.23, 95% CI:1.040-4.761), and self-reported increased appetite after 6 months of DMPA use (OR 3.06, 95% CI 1.505-6.214). CONCLUSION: Most DMPA users who gain excessive weight experience more than a 5% weight increase within 6 months. These data help physicians predict who is at risk of excessive gain and counsel them appropriately. LEVEL OF EVIDENCE: II.

AB - OBJECTIVE: To examine if early weight gain in depot medroxyprogesterone acetate (DMPA) users predicts continued excessive weight gain and to identify risk factors of early weight gain in DMPA users. METHODS: Depot medroxyprogesterone acetate users (N=240) were assessed before initiating contraception and every 3 months for 36 months. Early weight gain was defined as more than 5% baseline weight gain within 6 months of DMPA use. Mean weight gain at 6-month intervals was estimated based on early weight gain status (at or below 5% gain compared with above 5% gain). Multiple logistic and mixed-model regression analyses were used. RESULTS: About one-fourth of DMPA users had early weight gain. The mean weight gain of the at or below 5% group and above 5% group was 0.63 kg and 8.04 kg, 1.48 kg and 10.86 kg, and 2.49 kg and 11.08 kg after 12, 24, and 36 months (P<.001 at all observations), respectively. Early weight gainers also had a much steeper slope of weight gain over time than the regular weight gainers (0.35 kg/month compared with 0.08 kg/month, P<.001). Risk factors for early weight gain were body mass index less than 30 (odds ratio [OR] 4.00, 95% confidence interval [CI] 1.513-10.455), parity (OR 2.23, 95% CI:1.040-4.761), and self-reported increased appetite after 6 months of DMPA use (OR 3.06, 95% CI 1.505-6.214). CONCLUSION: Most DMPA users who gain excessive weight experience more than a 5% weight increase within 6 months. These data help physicians predict who is at risk of excessive gain and counsel them appropriately. LEVEL OF EVIDENCE: II.

UR - http://www.scopus.com/inward/record.url?scp=68949136625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949136625&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181af68b2

DO - 10.1097/AOG.0b013e3181af68b2

M3 - Article

VL - 114

SP - 279

EP - 284

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART 1

ER -